StreetInsider.com News Articles

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ:

Wed, 28 Oct 2026 08:00:44 -0400

PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Erasca, Inc. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

The Simply Goods Group (SMPL) PT Lowered to $18 at Stifel

Wed, 28 Oct 2026 04:45:18 -0400

Stifel analyst Matthew Smith lowered the price target on The Simply Goods Group (NASDAQ: SMPL) to $18.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "Simply reported a better than expected 4Q26 against low expectations, with EBITDA of $57.5 million $4.4 million ahead of our estimate behind stronger sales and gross margin, while initial FY27 guidance was below our estimate for revenue with EBITDA well below as the company reinvests a meaningful portion of its margin recovery behind its brands. The FY27 outlook calls for a 13%-17% sales decline and a 9%-14% EBITDA decline, with turnaround progress first evidenced

The Simply Goods Group (SMPL) PT Lowered to $18 at Stifel

Wed, 28 Oct 2026 04:45:18 -0400

Stifel analyst Matthew Smith lowered the price target on The Simply Goods Group (NASDAQ: SMPL) to $18.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "Simply reported a better than expected 4Q26 against low expectations, with EBITDA of $57.5 million $4.4 million ahead of our estimate behind stronger sales and gross margin, while initial FY27 guidance was below our estimate for revenue with EBITDA well below as the company reinvests a meaningful portion of its margin recovery behind its brands. The FY27 outlook calls for a 13%-17% sales decline and a 9%-14% EBITDA decline, with turnaround progress first evidenced

Jefferies Downgrades The Simply Goods Group (SMPL) to Hold

Wed, 28 Oct 2026 03:19:50 -0400

Jefferies analyst Kaumil Gajrawala downgraded The Simply Goods Group (NASDAQ: SMPL) from Buy to Hold with a price target of $11.00 (from $15.00).
The analyst comments: “F27 looks set to be an even tougher year for Simply. Management is making the right moves, in our view, but it will take several quarters to know if they work. Q1 starts with sales down 19-22% and Adj. EBITDA down 28-33%. Gross margins are moving higher, but that's only part of it. The top line needs to return to growth, but we have limited visibility into when that will happen. Until then, it's hard

Jefferies Downgrades The Simply Goods Group (SMPL) to Hold

Wed, 28 Oct 2026 03:19:50 -0400

Jefferies analyst Kaumil Gajrawala downgraded The Simply Goods Group (NASDAQ: SMPL) from Buy to Hold with a price target of $11.00 (from $15.00).
The analyst comments: “F27 looks set to be an even tougher year for Simply. Management is making the right moves, in our view, but it will take several quarters to know if they work. Q1 starts with sales down 19-22% and Adj. EBITDA down 28-33%. Gross margins are moving higher, but that's only part of it. The top line needs to return to growth, but we have limited visibility into when that will happen. Until then, it's hard

Form 10-K Simply Good Foods Co For: Aug 29

Tue, 27 Oct 2026 08:36:00 -0400
si-local-file:///var/storage/secattach/20261027/27237466.html

Simply Good Foods (SMPL) Tops Q4 EPS by 2c

Tue, 27 Oct 2026 07:05:06 -0400

Simply Good Foods (NASDAQ: SMPL) reported Q4 EPS of $0.44, $0.02 better than the analyst estimate of $0.42. Revenue for the quarter came in at $333.3 million versus the consensus estimate of $327.9 million.
For earnings history and earnings-related data on Simply Good Foods (SMPL) click here.

Form 8-K Simply Good Foods Co For: Oct 27

Tue, 27 Oct 2026 07:03:00 -0400
si-local-file:///var/storage/secattach/20261027/27236579.html

The Simply Good Foods Company Reports Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial Results and Provides Fiscal Year 2027 Outlook

Tue, 27 Oct 2026 07:00:00 -0400

DENVER, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking category, today reported financial results for the thirteen and fifty-two weeks ended August 29, 2026.

Fourth Quarter Summary:(1)

Net sales of $333.3 million versus $369.0 million
Net income of $30.5 million versus net loss of $12.4 million
Earnings per diluted share of $0.34 versus loss per diluted share of $0.12
Adjusted Diluted EPS(2) of $0.44 versus $0.46
Adjusted EBITDA(3) $57.5 million versus $66.2 million

The Simply Good Foods Company Reports Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial Results and Provides Fiscal Year 2027 Outlook

Tue, 27 Oct 2026 07:00:00 -0400

DENVER, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking category, today reported financial results for the thirteen and fifty-two weeks ended August 29, 2026.

Fourth Quarter Summary:(1)

Net sales of $333.3 million versus $369.0 million
Net income of $30.5 million versus net loss of $12.4 million
Earnings per diluted share of $0.34 versus loss per diluted share of $0.12
Adjusted Diluted EPS(2) of $0.44 versus $0.46
Adjusted EBITDA(3) $57.5 million versus $66.2 million

The Simply Goods Group (SMPL) PT Lowered to $12 at DA Davidson Ahead of Q4 Earnings

Mon, 26 Oct 2026 09:48:22 -0400
(Updated - October 26, 2026 9:48 AM EDT)
DA Davidson analyst Matt Curtis lowered the price target on The Simply Goods Group (NASDAQ: SMPL) to $12.00 (from $14.00) while maintaining a Neutral rating.
The analyst commented, "Ahead of F4Q results (10/27), we maintain our sales est but are trimming adj EBITDA to $53m (from $54m; guidance $52-57m) on modestly higher selling/marketing and G&A assumptions. While SMPL’s healthy balance sheet, profitable brands, and exposure to the growing purposeful nutrition category support LT optimism, we believe its current valuation of ~6x our CY26 EBITDA est is warranted given limited visibility on the timing of

The Simply Goods Group (SMPL) PT Lowered to $12 at DA Davidson Ahead of Q4 Earnings

Mon, 26 Oct 2026 09:48:22 -0400
(Updated - October 26, 2026 9:48 AM EDT)
DA Davidson analyst Matt Curtis lowered the price target on The Simply Goods Group (NASDAQ: SMPL) to $12.00 (from $14.00) while maintaining a Neutral rating.
The analyst commented, "Ahead of F4Q results (10/27), we maintain our sales est but are trimming adj EBITDA to $53m (from $54m; guidance $52-57m) on modestly higher selling/marketing and G&A assumptions. While SMPL’s healthy balance sheet, profitable brands, and exposure to the growing purposeful nutrition category support LT optimism, we believe its current valuation of ~6x our CY26 EBITDA est is warranted given limited visibility on the timing of

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Compan

Mon, 26 Oct 2026 08:51:57 -0400

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects